Looking at $RXRX.
This is a company I recently got into. I really think what they are doing is very cool. I have been taking my time and going through everything I could about them. Now I am here to share it all with you.
1/ This company is all about using robots to do millions of experiments and record the data. They feed all that data into a super computer and turn it into a platform that can develop drugs.
2/ The statistics show that it takes well over $1 billion per drug for development and 90% of those drugs fail to ever reach commercial. That cost of drug development is way too high. Using AI and machine learning, they can reduce those costs and increase the success.
3/ This is the kind of platform that can yield a huge output of development candidates that can be developed wholly or with partners. They have a ton of potential for collaborations. They have 1 so far with Bayer.
4/ They have 4 assets going into phase 2 in 2022 and multiple other program in early discovery. For a company with 4 phase 2 assets, they seem fairly cheap at around $3 billion market cap. There are phase 1 companies trading at 2x that price.
5/ Their first drug is a MEK inhibitor. The first thing I thought was "Oh God, not another MEK inhibitor". This does work differently as its designed to stay in the intestine where its needed for APC instead of being absorbed into the body.
6/ I went over their phase 1 safety data, and I did find it a bit concerning. I will wait to see the phase 2 data.
7/ Their second drug is a HDAC inhibitor. This is another one that might seem to be very competitive at this point, but again, this one has CNS penetration to target Neurofibromitosis. I went through the phase 1 safety data and it looked good so far.
8/ Their second asset targets GSK3Beta which I think is another part of the Insulin pathway if I recall correctly. The early safety data looked good.
9/ The last drug they have in the clinic is for CCM. Its a superoxide scavenger molecule. The safety data that I saw looked good.
10/ The last part about the company that I still haven't really gotten to know that well is the management. That part will take time. Overall, I think its a fantastic company, with really cool science and at a very reasonable valuation.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.